Table 4.

Coefficient estimates for the average effect of time of ARV regimen change on new endpoints for n = 182 participants who experience virological failure on an efavirenz-containing regimen. New endpoints are defined as length-adjusted AUCs from the time of virologic failure to the end of study. Time is modeled in weeks and centered at M = 10 weeks.

	Length-adjusted AUC				Last 2 HIV-1 RNA Obs.
Dose	HIV-1 RNA		Days below LOD		Case 1†		Case 2†
Model	Est.	SE	Est.	SE	Est.	SE	Est.	SE
Linear
β0	2.572	0.100	0.356	0.031	−0.507	0.190	−0.012	0.188
β1	0.007	0.013	−0.004	0.004	−0.035	0.024	−0.042	0.023
Quadratic
β0	2.882	0.163	0.267	0.054	−0.972	0.387	−0.581	0.377
β1	0.008	0.010	−0.005	0.003	−0.036	0.020	−0.045	0.020
β2	−0.005	0.002	0.002	0.001	0.008	0.005	0.010	0.005

^†Case 1 uses a binary outcome with success defined as two final HIV-1 RNA measurements below 200 copies/mL. Case 2 uses a binary outcome with success defined as at least one of two final HIV-1 RNA measurements below 200 copies/mL (See also Table 1).

NOTE: Abbreviations used: limit of detection (LOD), coefficient estimate (Est.), standard error estimate (SE).